Apellis Pharmaceuticals chief development officer sells $8,207 in stock
Jeffrey Eisele, the Chief Development Officer at Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a $3.8 billion market cap biopharmaceutical company, recently sold a portion of his holdings in the ...
Apellis Pharmaceuticals chief scientific officer sells $24,386 in stock
Pascal Deschatelets, the Chief Scientific Officer of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), recently sold 826 shares of the company's common stock. The shares were sold at an average price of ...